Werewolf Therapeutics Inc (HOWL)

$2.77

-0.11

(-3.82%)

Market is closed - opens 7 PM, 19 Jul 2024

Performance

  • $2.73
    $3.05
    $2.77
    downward going graph

    1.44%

    Downside

    Day's Volatility :10.43%

    Upside

    9.12%

    downward going graph
  • $1.57
    $8.19
    $2.77
    downward going graph

    43.32%

    Downside

    52 Weeks Volatility :80.83%

    Upside

    66.18%

    downward going graph

Returns

PeriodWerewolf Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-53.05%
5.9%
0.0%
6 Months
-34.52%
5.5%
0.0%
1 Year
-17.31%
10.9%
0.0%
3 Years
-83.52%
15.6%
-17.0%

Highlights

Market Capitalization
125.2M
Book Value
$2.72
Earnings Per Share (EPS)
-1.1
Wall Street Target Price
12.5
Profit Margin
-256.33%
Operating Margin TTM
-2312.94%
Return On Assets TTM
-15.24%
Return On Equity TTM
-34.84%
Revenue TTM
16.2M
Revenue Per Share TTM
0.43
Quarterly Revenue Growth YOY
-83.39999999999999%
Gross Profit TTM
-37.4M
EBITDA
-43.6M
Diluted Eps TTM
-1.1
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.54
EPS Estimate Next Year
-1.49
EPS Estimate Current Quarter
-0.35
EPS Estimate Next Quarter
-0.32

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Werewolf Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 351.26%

Current $2.77
Target $12.50

Technicals Summary

Sell

Neutral

Buy

Werewolf Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Werewolf Therapeutics Inc
Werewolf Therapeutics Inc
2.97%
-34.52%
-17.31%
-83.52%
-82.8%
Moderna, Inc.
Moderna, Inc.
-9.73%
21.69%
-3.08%
-61.31%
759.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
2.19%
14.34%
48.43%
82.37%
258.01%
Novo Nordisk A/s
Novo Nordisk A/s
-7.8%
21.53%
62.25%
194.33%
441.74%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.55%
12.21%
36.13%
144.99%
180.32%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Werewolf Therapeutics Inc
Werewolf Therapeutics Inc
0.66
NA
NA
-1.54
-0.35
-0.15
NA
2.72
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
32.06
32.06
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
48.58
48.58
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.67
31.67
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Werewolf Therapeutics Inc
Werewolf Therapeutics Inc
Buy
$125.2M
-82.8%
0.66
-256.33%
Moderna, Inc.
Moderna, Inc.
Buy
$48.0B
759.82%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$119.6B
258.01%
32.06
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$631.0B
441.74%
48.58
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
180.32%
31.67
39.46%

Insights on Werewolf Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 8.08M → 742.0K (in $), with an average decrease of 50.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, -5.09M → -16.19M (in $), with an average decrease of 47.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 62.3% return, outperforming this stock by 79.6%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 194.3% return, outperforming this stock by 277.8%

Institutional Holdings

  • RA Capital Management, LLC

    14.18%
  • Mpm Asset Management, LLC

    9.88%
  • Partner Fund Management LP

    6.94%
  • Adage Capital Partners Gp LLC

    6.92%
  • MPM Oncology Impact Management LP

    5.51%
  • Bank of America Corp

    4.34%

Company Information

we are an immuno-oncology company advancing a pipeline of next generation, transformative cancer treatments.

Organization
Werewolf Therapeutics Inc
Employees
46
CEO
Dr. Daniel J. Hicklin Ph.D.
Industry
Services

FAQs